131 related articles for article (PubMed ID: 35293739)
1. Dimerization of the Peptide CXCR4-Antagonist on Macromolecular and Supramolecular Protraction Arms Affords Increased Potency and Enhanced Plasma Stability.
Harms M; Hansson RF; Carmali S; Almeida-Hernández Y; Sanchez-Garcia E; Münch J; Zelikin AN
Bioconjug Chem; 2022 Apr; 33(4):594-607. PubMed ID: 35293739
[TBL] [Abstract][Full Text] [Related]
2. Development of N-Terminally Modified Variants of the CXCR4-Antagonistic Peptide EPI-X4 for Enhanced Plasma Stability.
Harms M; Fabech Hansson R; Gilg A; Almeida-Hernández Y; Löffler J; Rodríguez-Alfonso A; Habib MMW; Albers D; Ahmed NS; Abadi AH; Winter G; Rasche V; Beer AJ; Weidinger G; Preising N; Ständker L; Wiese S; Sanchez-Garcia E; Zelikin AN; Münch J
J Med Chem; 2023 Nov; 66(22):15189-15204. PubMed ID: 37940118
[TBL] [Abstract][Full Text] [Related]
3. Proteolytic processing of human serum albumin generates EPI-X4, an endogenous antagonist of CXCR4.
Zirafi O; Hermann PC; Münch J
J Leukoc Biol; 2016 Jun; 99(6):863-8. PubMed ID: 26965637
[TBL] [Abstract][Full Text] [Related]
4. Advanced EPI-X4 Derivatives Covalently Bind Human Serum Albumin Resulting in Prolonged Plasma Stability.
Rodríguez-Alfonso A; Heck A; Ruiz-Blanco YB; Gilg A; Ständker L; Kuan SL; Weil T; Sanchez-Garcia E; Wiese S; Münch J; Harms M
Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36499357
[TBL] [Abstract][Full Text] [Related]
5. Discovery and characterization of an endogenous CXCR4 antagonist.
Zirafi O; Kim KA; Ständker L; Mohr KB; Sauter D; Heigele A; Kluge SF; Wiercinska E; Chudziak D; Richter R; Moepps B; Gierschik P; Vas V; Geiger H; Lamla M; Weil T; Burster T; Zgraja A; Daubeuf F; Frossard N; Hachet-Haas M; Heunisch F; Reichetzeder C; Galzi JL; Pérez-Castells J; Canales-Mayordomo A; Jiménez-Barbero J; Giménez-Gallego G; Schneider M; Shorter J; Telenti A; Hocher B; Forssmann WG; Bonig H; Kirchhoff F; Münch J
Cell Rep; 2015 May; 11(5):737-47. PubMed ID: 25921529
[TBL] [Abstract][Full Text] [Related]
6. A peptide derived from bee venom-secreted phospholipase A2 inhibits replication of T-cell tropic HIV-1 strains via interaction with the CXCR4 chemokine receptor.
Fenard D; Lambeau G; Maurin T; Lefebvre JC; Doglio A
Mol Pharmacol; 2001 Aug; 60(2):341-7. PubMed ID: 11455021
[TBL] [Abstract][Full Text] [Related]
7. Conformational States of the CXCR4 Inhibitor Peptide EPI-X4-A Theoretical Analysis.
Jung CK; Münch J; Jacob T
Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003419
[TBL] [Abstract][Full Text] [Related]
8. Ligand selectivity of a synthetic CXCR4 mimetic peptide.
Groß A; Brox R; Damm D; Tschammer N; Schmidt B; Eichler J
Bioorg Med Chem; 2015 Jul; 23(14):4050-5. PubMed ID: 25801155
[TBL] [Abstract][Full Text] [Related]
9. Peptide Bispecifics Inhibiting HIV-1 Infection by an Orthogonal Chemical and Supramolecular Strategy.
Schauenburg D; Zech F; Heck AJ; von Maltitz P; Harms M; Führer S; Alleva N; Münch J; Kuan SL; Kirchhoff F; Weil T
Bioconjug Chem; 2023 Sep; 34(9):1645-1652. PubMed ID: 37665137
[TBL] [Abstract][Full Text] [Related]
10. Mutations That Increase the Stability of the Postfusion gp41 Conformation of the HIV-1 Envelope Glycoprotein Are Selected by both an X4 and R5 HIV-1 Virus To Escape Fusion Inhibitors Corresponding to Heptad Repeat 1 of gp41, but the gp120 Adaptive Mutations Differ between the Two Viruses.
Zhuang M; Vassell R; Yuan C; Keller PW; Ling H; Wang W; Weiss CD
J Virol; 2019 Jun; 93(11):. PubMed ID: 30894471
[TBL] [Abstract][Full Text] [Related]
11. Raft localization of CXCR4 is primarily required for X4-tropic human immunodeficiency virus type 1 infection.
Kamiyama H; Yoshii H; Tanaka Y; Sato H; Yamamoto N; Kubo Y
Virology; 2009 Mar; 386(1):23-31. PubMed ID: 19178925
[TBL] [Abstract][Full Text] [Related]
12. Distinct molecular pathways to X4 tropism for a V3-truncated human immunodeficiency virus type 1 lead to differential coreceptor interactions and sensitivity to a CXCR4 antagonist.
Del Prete GQ; Leslie GJ; Haggarty B; Jordan AP; Romano J; Hoxie JA
J Virol; 2010 Sep; 84(17):8777-89. PubMed ID: 20573813
[TBL] [Abstract][Full Text] [Related]
13. Suppression of dualtropic human immunodeficiency virus type 1 by the CXCR4 antagonist AMD3100 is associated with efficiency of CXCR4 use and baseline virus composition.
Fransen S; Bridger G; Whitcomb JM; Toma J; Stawiski E; Parkin N; Petropoulos CJ; Huang W
Antimicrob Agents Chemother; 2008 Jul; 52(7):2608-15. PubMed ID: 18443125
[TBL] [Abstract][Full Text] [Related]
14. Identification of an unique CXCR4 epitope whose ligation inhibits infection by both CXCR4 and CCR5 tropic human immunodeficiency type-I viruses.
Adachi T; Tanaka R; Kodama A; Saito M; Takahashi Y; Ansari AA; Tanaka Y
Retrovirology; 2011 Oct; 8():84. PubMed ID: 22018245
[TBL] [Abstract][Full Text] [Related]
15. Computational modeling and experimental validation of the EPI-X4/CXCR4 complex allows rational design of small peptide antagonists.
Sokkar P; Harms M; Stürzel C; Gilg A; Kizilsavas G; Raasholm M; Preising N; Wagner M; Kirchhoff F; Ständker L; Weidinger G; Mayer B; Münch J; Sanchez-Garcia E
Commun Biol; 2021 Sep; 4(1):1113. PubMed ID: 34552197
[TBL] [Abstract][Full Text] [Related]
16. Complex determinants in human immunodeficiency virus type 1 envelope gp120 mediate CXCR4-dependent infection of macrophages.
Ghaffari G; Tuttle DL; Briggs D; Burkhardt BR; Bhatt D; Andiman WA; Sleasman JW; Goodenow MM
J Virol; 2005 Nov; 79(21):13250-61. PubMed ID: 16227248
[TBL] [Abstract][Full Text] [Related]
17. Regulation of CXCR4 receptor dimerization by the chemokine SDF-1alpha and the HIV-1 coat protein gp120: a fluorescence resonance energy transfer (FRET) study.
Toth PT; Ren D; Miller RJ
J Pharmacol Exp Ther; 2004 Jul; 310(1):8-17. PubMed ID: 15014135
[TBL] [Abstract][Full Text] [Related]
18. Anti-HIV-1 peptide derivatives based on the HIV-1 Co-receptor CXCR4.
Hashimoto C; Nomura W; Narumi T; Fujino M; Tsutsumi H; Haseyama M; Yamamoto N; Murakami T; Tamamura H
ChemMedChem; 2013 Oct; 8(10):1668-72. PubMed ID: 24039179
[TBL] [Abstract][Full Text] [Related]
19. A novel peptide antagonist of CXCR4 derived from the N-terminus of viral chemokine vMIP-II.
Zhou N; Luo Z; Luo J; Hall JW; Huang Z
Biochemistry; 2000 Apr; 39(13):3782-7. PubMed ID: 10736178
[TBL] [Abstract][Full Text] [Related]
20. Dissociation of the signalling and antiviral properties of SDF-1-derived small peptides.
Heveker N; Montes M; Germeroth L; Amara A; Trautmann A; Alizon M; Schneider-Mergener J
Curr Biol; 1998 Mar; 8(7):369-76. PubMed ID: 9545196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
